Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708925 | 1.00 | P2RX7 (0.50) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL2026657 | 0.85 | KDM4E (0.42) | MEN1KMT2AKDM4E | |
| SCHEMBL2026659 | 0.85 | KDM4E (0.42) | MEN1KMT2AKDM4E | |
| SCHEMBL1580849 | 0.84 | P2RX7 (0.50) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL1580848 | 0.84 | P2RX7 (0.50) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL9768783 | 0.80 | HSP90AA1 (0.53) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL4474742 | 0.79 | P2RX7 (0.50) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL4474740 | 0.79 | P2RX7 (0.50) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL2240381 | 0.79 | ADORA3 (0.47) | P2RX7NOS3NOS2GRM5HSP90AA1 | |
| SCHEMBL2027602 | 0.79 | ECE1 (0.35) | HSP90AA1CCR1CCR8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| CN-102361872-B | Fused pyrimidines as AKT inhibitors | BAYER SCHERING PHARMA AG | 2014-12-03 | — | — | CN | disclosed |
| US-20130317002-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | US | disclosed |
| US-20130310362-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2013-11-21 | — | — | US | disclosed |
| EP-2396331-B1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER IP GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| CN-102361872-A | Fused pyrimidines as AKT inhibitors | BAYER SCHERING PHARMA AG | 2012-02-22 | — | — | CN | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2396331-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091824-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317002-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, TYMS | P2RX7 291/4885NOS3 506/4885NOS2 508/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | P2RX7 1072/4885NOS3 1553/4885NOS2 2359/4885 |
| US-20130310362-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, PIK3CD | P2RX7 283/4885NOS3 310/4885NOS2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.